JOVANA
Library Glossary Getting Started Three Levels Fields How it works Mission
Join the mission
All guides

Oral Drugs for Type 2 Diabetes: Metformin and Friends

Type 2 diabetes is a different problem — the body still makes insulin but ignores it. The drugs reflect that: metformin makes the body listen better, sulfonylureas squeeze out more insulin, and GLP-1 agonists work with the gut's own signals. See how matching mechanism to problem keeps patients safe.

A different disease needs a different idea

In type 2 diabetes the pancreas still makes insulin, but the body's tissues have become deaf to it — this is *insulin resistance*. Over years the strain wears the pancreas down too. Because some insulin is still present, treatment can often start with tablets rather than injections; these are the oral hypoglycaemic drugs, taken by the convenient oral route. Each drug class attacks the problem from a different angle, and knowing the mechanism of action tells you its risks.

Metformin: the sensible first choice

Metformin is the usual first drug worldwide. Its main move is to tell the liver to stop overproducing glucose, and it also helps muscle listen to insulin again. Crucially, it does *not* force the pancreas to release more insulin, so on its own it almost never causes hypoglycaemia — a big safety advantage. Its common nuisance is gut upset (nausea, loose stools), usually eased by starting low and taking it with food.

Sulfonylureas and GLP-1 agonists: push versus partner

A sulfonylurea takes the opposite approach to metformin: it pushes the pancreas to release more insulin, regardless of the current glucose level. That makes it effective but means it *can* cause hypoglycaemia and tends to add weight. Because it forces a tiring pancreas to work harder, its effect can fade over years as the gland gives out.

A GLP-1 receptor agonist works more gently and cleverly. It copies a gut hormone released when you eat, prompting insulin release only when glucose is high, slowing stomach emptying, and reducing appetite. The result is good glucose control with weight loss and little hypoglycaemia. Most are injected, though oral forms now exist; nausea is the common early side effect.

  1. Match mechanism to risk: drugs that *raise insulin regardless of glucose* (sulfonylureas) can cause hypoglycaemia.
  2. Drugs that *only act when glucose is high* (metformin, GLP-1 agonists) rarely do — a key talking point with patients.
  3. Therapy is built in steps: start with metformin, then add a second class chosen for the individual's weight, kidneys, and heart.